~8 min read · 1,772 words
Open questions — Lightwave Logic (LWLG)
Things this knowledge base does not yet resolve. Each is tagged with a research path. Last updated 2026-04-26.
Customer / pipeline
| # | Question | Research path |
|---|---|---|
| Q1 | Who are the 4 Stage-3 Fortune Global 500 customers? | Watch 8-K disclosures, foundry-side announcements, hiring patterns at LWLG, joint-paper bylines, patent co-assignments |
| Q2 | What is the Stage-3 cohort start date for each of the 4? Some may have entered earlier and be closer to Stage-4 conversion than others | Listen for AGM 2026 commentary; track LeMaitre conference Q&A |
| Q3 | What is the per-modulator ASP / royalty rate LWLG is internally modeling? | Watch for first commercial-PO disclosure; cross-check vs UDC OLED royalty patterns |
| Q4 | Which of LWLG’s 15+ Stage-1/2 cohort are most likely to advance to Stage-3 in 2026? | LeMaitre cadence at quarterly updates; OFC/ECOC 2026 mentions |
| Q5 | Is there any Marvell direct-customer relationship beyond the Polariton-supplied stack? | Watch for direct LWLG-Marvell supply agreement filing; LinkedIn signals |
Foundry / partner
| # | Question | Research path |
|---|---|---|
| F1 | Which of LWLG’s foundry partners has the deepest qualification-pathway lead (GF Fotonix, Tower PH18, SilTerra, AMF)? | Monitor foundry-side OFC/ECOC presentations; LinkedIn engineer-roster shifts |
| F2 | Are TSMC and Samsung in LWLG’s “unnamed foundry” pool (per prototype_101 IH speculation)? | Conference signals; engineering-resource constraint commentary |
| F3 | What is the integration economics: per-wafer LWLG fee vs per-modulator royalty vs hybrid? | First foundry MSA disclosure; IR commentary at AGM |
| F4 | Marvell-Polariton: what is the supply agreement structure for the polymer feed? | 10-K disclosure post-merger; KPMG advisory disclosure |
Technology
| # | Question | Research path |
|---|---|---|
| T1 | What is LWLG’s worst-case process yield demonstrated at production wafer scale? | Foundry-side disclosure; possibly via published joint papers |
| T2 | How many photo-stability hours have LWLG modulators accumulated in CW high-power CPO duty cycle? | LWLG technical PR; IEEE/Optica publications |
| T3 | How does LWLG’s Series-3 chromophore generation differ from Indigo / NR / Malachite predecessors? | Peer-reviewed papers + LWLG patent filings |
| T4 | Can LWLG support the 8” → 12” wafer scaling required by leading SiPh foundries (TSMC) without process changes? | Foundry / LWLG joint papers |
| T5 | What is the failure-mode profile beyond Telcordia 85/85 — specifically humidity at 95/95, thermal cycling, mech-shock? | Subsequent reliability disclosures |
Capital / financial
| # | Question | Research path |
|---|---|---|
| K1 | What is LWLG’s current burn rate (Q1 2026 quarterly)? | Q1 2026 10-Q (filing ~May 8 2026) |
| K2 | How much of the $51.4M Roth ATM shelf has been used? Remaining capacity? | Form 8-K; 10-Q filings |
| K3 | Will LWLG need another raise in 2027? At what price? | Quarterly monitoring; Stage-4 progress |
| K4 | What is the breakdown of insider holdings vs institutional vs retail? | 10-K + 13F filings |
| K5 | What’s the Davidson Kempner / Citadel / Alyeska investment thesis? Are they hedged? | 13F + 13G/D filings; cross-check vs short interest |
IP / patent
Update 2026-04-27 — primary-source patent validation: LWLG portfolio is 22 distinct inventions / 35 US grants (USPTO + Google Patents + EPO Espacenet by-assignee enumeration). Aggregator counts (Minesoft 47 families / 142 apps / 184 pubs / 52 grants; GreyB 78 patents / 41 granted / 29 families) reflect jurisdictional counterparts of the same inventions, not 25-50 hidden additional patents. Continuation chains run to 2038-2042. US 7,919,619 (Goetz sister patent) already expired Oct 26, 2025. 2 prior misattributions flagged: US-2024-0356517 is assigned to Murata Manufacturing (acoustic-wave device, NOT LWLG); US-12187945 is assigned to Polaris Electro-Optics (Cory Pecinovsky parallel filing). LWLG-NLM litigation collision verdict: 10-15% over 24 months; cross-license 5-10%; most-likely co-existence. See
kb/02_technology/ip_patents.md.
| # | Question | Research path |
|---|---|---|
| IP1 | Monitor any IPR petitions filed; track LWLG’s claim amendments | |
| IP2 | Are LWLG and NLM Photonics likely to enter a cross-licensing arrangement, or are they on a litigation collision course? Patent agent verdict: 10-15% formal-litigation probability over 24 months; most-likely co-existence (UDC/Kyulux duopoly model). Highest collision vector: architectural (cladding-stack), NOT chromophore chemistry. | Monitor C&D letters, 10-K disclosures; watch foundry-side parallel-tapeout patterns |
| IP3 | Patent-quality scoring (forward-citations, claim breadth, IPC class density) | |
| IP4 | Has LWLG attempted to file in China / Asia jurisdictions where foundry partners operate? | International patent records (EPO, JPO, KIPO, CIPO) |
| IP5 | What is HyperLight’s ~163-filing TFLN portfolio’s claim overlap with LWLG’s polymer claims? Could TFLN-side IP block LWLG materials in TFLN-substrate hybrid devices? | Cross-class IPC search; HyperLight’s recent grants vs LWLG’s hybrid filings |
Competitive
| # | Question | Research path |
|---|---|---|
| X1 | What is NLM Photonics’ actual customer pipeline — is it 3 Stage-3 equivalents like LWLG, or fewer? | Industry conference signals; private-company info via secondary sources |
| X2 | Will TFLN reach 800G/lane production by 2028, blocking LWLG’s window? | HyperLight + UMC roadmap; OFC/ECOC 2027 panels |
| X3 | What is the BTO TRL trajectory? Could it leapfrog EOP for 6.4T+? | IBM / Lumiphase publications |
| X4 | Will Marvell (post-Polariton) develop a competing in-house EO polymer chemistry? | Watch Marvell hiring; their materials-science footprint |
Market / commercial
| # | Question | Research path |
|---|---|---|
| M1 | What is the implied per-modulator ASP in the Jan 2026 deck’s $24B / 234M figure? Implied is ~$100/unit blended — looks high for AI/DC short-reach but reasonable for coherent DWDM | LightCounting subscriber data + cross-check vs Cignal AI / Dell’Oro |
| M2 | Will LightCounting revise its 2028 transceiver forecast given AI capex acceleration? | LightCounting publications |
| M3 | What is the per-customer LWLG revenue ramp profile in Stage-4? Linear, S-curve, or step-function? | First commercial-PO disclosure |
| M4 | How much of the SAM ($1-2.5B) does LWLG management internally target as 2028 revenue? | AGM commentary; investor day if scheduled |
| M5 | What is the actual implied gross margin of the Marvell-Polariton deal? Does it suggest LWLG margin economics? | Marvell post-acquisition disclosure |
Governance / corporate
Updates 2026-04-27 from AGM/market-data + LinkedIn agents: G2 substantially answered (board: Zelibor, El-Ahmadi, Connelly Jr., Ciesla, Partridge — DEF 14A 2026). G3 partially answered (Snizhana “Ana” Quan appointed Jan 6 2026; ex-public-company CFO experience to verify). G4 substantially answered (LeMaitre 2025 total comp ~$8.6M = $500K base + $4.83M RSU FV + $2.29M option FV; 158:1 equity-to-base ratio; comp consultants = Meridian + Aon dual advisor (NOT Pearl Meyer as some speculation suggested); Sept 2025 employment-agreement amendment extends term to Sep 2028).
| # | Question | Research path |
|---|---|---|
| G1 | Why did Lebby step aside in 2024? Was it operational performance, board direction, or personal? | LinkedIn / industry-source check; Lebby’s post-LWLG GenusTechnik Inc. + Optica Council Chair role suggests planned succession, not forced |
| G2 | AGM May 21 vote; new 8-K post-AGM | |
| G3 | LinkedIn deep-dive; SEC bio | |
| G4 | Watch 2027 comp committee actions | |
| G5 | What are Marcelli/Zelibor severance specifics? Quan/Chowdhury comp packages? Director comp table 2025? Equity-incentive plan name + remaining authorized shares? Audit/comp committee meeting counts in 2025? | Specific DEF 14A 2026 sections (gap-fill agent in flight) |
Macro / strategic
| # | Question | Research path |
|---|---|---|
| S1 | If AI capex pulls back to $5T (vs $7T McKinsey accelerated), how does LWLG’s TAM contract? | Sensitivity scenario modeling |
| S2 | If a major hyperscaler (Google, Microsoft) chooses to internally develop EO polymer chemistry, what’s the LWLG defense? | Watch hyperscaler photonics M&A activity |
| S3 | What is LWLG’s exit-via-acquisition probability in 2027-2028? Likely acquirers? | Pattern-match vs UDC, Smart Photonics, Lumera precedents |
| S4 | Will an LWLG quantum-PIC application emerge as a separate commercial unit? | Quantum sector signaling; QPICs partnership status |
Near-term hard catalysts (newly added 2026-04-27)
| # | Catalyst | Date | KB action when it lands |
|---|---|---|---|
| C1 | Russell Rank Day (LWLG ~$1.91B mcap → solid Russell 2000 inclusion likely) | Apr 30, 2026 (3 days from this refresh) | Append to 06_market_data/stock_price_history.md; effective Jun 26, 2026 |
| C2 | Q1 2026 10-Q (first quarter under new Quan CFO; expect first commercial PO disclosure if any) | ~May 8, 2026 | Update quarterly_trend.md + financials_summary.md |
| C3 | Apr-30 FINRA short-interest print (captures full Apr 22 ATH window) | ~May 11, 2026 | Append to short_interest_series.md |
| C4 | True Q1 2026 13Fs (captures Tower-deal flow + Marvell-Polariton flow + ATH-window flow) | ~May 15, 2026 | Append to institutional_holders.md (note: prior 13F load was Q4 2025 period-of-record) |
| C5 | AGM virtual meeting (2 director seats + Stephano Slack ratification + management commentary) | May 21, 2026 | Live-capture commentary into earnings_calls.md |
| C6 | Russell reconstitution effective (passive-flow window) | Jun 26, 2026 | Capture passive-flow signal in 06_market_data/ |
”Known unknowns” we cannot research from public information
These require direct primary-source access (management interview, technical demo, NDA-bound partnership):
- Specific customer-program technical specifications (Vπ targets, BER profiles, qualification regimes)
- Competing-platform internal cost structures (TFLN, BTO)
- Hyperscaler internal modulator-supply preferences (anonymous vs branded)
- Board-level discussions on cap-table strategy
Process note: the above questions form the watchlist for ongoing monitoring. Each quarterly and major-event cycle should resolve 3-5 of these. The “open questions” file should be updated alongside any new disclosures.